Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sunrun Inc (RUN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Sunrun (RUN) trades at $12.47, up 0.08% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a net income margin of 17.88% and ROE of 19.06%, while launching a distributed AI data center pilot to leverage its home energy assets. Analyst consensus is bullish with a $17.45 price target, but cash flow from operations remains negative, highlighting financial strain.

The outlook for RUN is mixed: growth potential from virtual power plant initiatives and AI partnerships offers upside, but negative operating cash flow and high debt pose significant risks. Investors should weigh the attractive valuation multiples against operational sustainability and market volatility.